Curated News
By: NewsRamp Editorial Staff
July 24, 2024
Annovis Bio Welcomes New Executive Team Members
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- The addition of seasoned professionals to Annovis Bio's executive team positions the company for success in bringing its flagship drug candidate buntanetap to market.
- The new executive team members, including Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen, will play a crucial role in advancing Annovis Bio's flagship drug candidate buntanetap closer to NDA status and market release.
- Annovis Bio's progress toward bringing transformative therapies for neurodegenerative disorders like Alzheimer’s Disease and Parkinson’s Disease to market has the potential to improve the lives of countless individuals and their families.
- The addition of seasoned professionals to Annovis Bio's executive team marks a pivotal moment for the company as it makes strides toward bringing transformative therapies for neurodegenerative disorders closer to market.
Impact - Why it Matters
This news matters because it signifies a significant step forward for Annovis Bio in its mission to develop transformative therapies for neurodegenerative disorders. The addition of seasoned professionals to the executive team indicates the company's commitment to advancing its drug candidate and bringing potential treatments for Alzheimer's Disease and Parkinson's Disease closer to market.
Summary
Annovis Bio (NYSE: ANVS) has added four new members to its executive team, including Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen. These additions are crucial as the company works towards advancing its flagship drug candidate buntanetap towards New Drug Application (“NDA”) status and to market.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Annovis Bio Welcomes New Executive Team Members
